Regenerative Medicine Market Growth Probability, Key Vendors and Future Scenario Up To 2022-2030

Regenerative Medicine Market Outlook 2028

The global regenerative medicine market was valued at US$ 6 Bn in 2020

It is estimated to expand at a CAGR of 10.3% from 2021 to 2028

The global regenerative medicine market is expected to reach the value of US$ 12.9 Bn by the end of 2028

Get the sample copy of report@ https://qyresearchmedical.com/sample/111476

Analysts’ Viewpoint on Regenerative Medicine Market Scenario

Mesenchymal stem cells are being publicized for exerting therapeutic effects through the induction of immune responses and neutralizing antibody titers among COVID-19 patients. Regenerative medicine offers various cell-tissue therapeutics and related products, such as stem cell therapy, natural killer (NK) cell therapy, Chimeric antigen receptor (CAR) T cell therapy, exosomes, and tissue products. However, lack of awareness and risk of complications in patients are inhibiting market growth. Hence, aspiring market players and established companies entering the fray should bolster R&D investments to increase the availability of effective products in order to prevent patient complications. Stakeholders should educate patients about the risks and benefits of regenerative medicine to improve clinical outcomes & help them make informed treatment decisions.

Marketing Helps to Increase Visibility and Awareness about Regenerative Medicines

A large pool of elderly worldwide population and the rising instances of external & internal injuries have led to increasing uptake of regenerative medicines, especially for bone & joint injuries. However, this is a relatively new concept, which promotes the human body’s natural capacity to heal. Thus, to increase awareness about regenerative medicine, healthcare facilities are investing in advertising & marketing such as setting up standees in hospitals to increase visibility about therapeutics.

Another factor that has served to boost the global regenerative medicine market is the technological progress in biomaterials. Despite such tailwinds, however, the market is yet to reach its full potential, owing to regulatory constraints, complications & infections, and other ethical concerns.

View full report@ https://qyresearchmedical.com/report/regenerative-medicine-market-technology-stem-cell-biomaterial-and-tissue-engineering-and-application-bone-graft-substitutes-osteoarticular-diseases-allogeneic-bones-autogenic-bones-and-others-global-ind-2021-2028/111476

The regenerative medicine market at present is in the nascent stage, and hence has a strong potential to grow in the near future. Hence, many aspiring players are entering the fray and are upping the ante against their well-entrenched counterparts with more effective products. This is also expected to heat up competition in the market for regenerative medicine, which at present is fragmented and requires R&D investment.

 COVID-19 Patient Outcomes

Since healthcare companies are under scrutiny for increasing treatment options for COVID-19 and its variants such as NeoCoV & Omicron, stakeholders in the regenerative medicine market are taking this opportunity to boost their R&D capabilities. Stakeholders are collaborating with experts to increase studies in order to find the best therapeutic approach for the novel infection. This has led to findings in mesenchymal stem cells (MSCs) that help to reduce inflammatory symptoms and protect against cytokine storm which critically contributes to the COVID-19 progression in patients.

Can Market Revenue of Stem Cells Surpass Biomaterials During Forecast Period?

The regenerative medicine market has been broadly divided on the basis of technology into biomaterials, stem cell therapy, and tissue engineering. Of these, the stem cell technology holds maximum potential in the market at present. It is a bio-based alternative that is gaining traction in spite of the swift development of synthetic options. This can be ascribed to the high generative capacity of the stem cells that brings about production of other cells in the body. Not only in bone and joint disorders, regenerative medicine also finds usage in treating retinal diseases, cancer, diabetes, Alzheimer’s, rheumatoid arthritis, cerebral palsy, autism spectrum, and others.

Moreover, stem cells are predicted to play a crucial role in regenerative medicine, which serves to treat the primary cause of the ailment, instead of the symptoms unlike other medicines. Many breakthroughs have already been reported in this direction. However, despite all the progress in the domain of the stem cell therapy, the segment of biomaterials accounts for a leading revenue share at present and is expected to retain its dominance.

Purchase Complete Report Now@ https://qyresearchmedical.com/report/checkout/111476/2900

U.S. and Asia Pacific Witness Increased R&D Investment in Regenerative Medicines

From a geographical standpoint, North America dominates the regenerative medicine market. This can be attributed to extensive, cutting-edge research and development (R&D) being carried out in the U.S. Large investment allocations by both government and private players are contributing toward the growth of the U.S. regenerative medicine market. Another reason for the dominance of North America is the large elderly population in the region who are highly susceptible to bone & joint issues and the high medical spends of the overall population.

Asia Pacific is another attractive region in the market for regenerative medicine. Numerous factors such as a strengthening healthcare infrastructure, large patient pool due to high population, surging awareness about regenerative medicines, and increasing ability of people to spend on better treatments are playing a key role in promoting market growth in this region. Japan is one of the main markets in this region, owing to fewer regulatory restraints, coupled with technological advancements in the area of regenerative medicine.

Regenerative Medicine Market: Overview

According to Transparency Market Research’s latest report on the global regenerative medicine market for the historical period 2017–2018 and forecast period 2021–2028, increase in demand for customized regenerative medicine is projected to drive the global regenerative medicine market during the forecast period

Key Driver

The incidence and prevalence of chronic diseases such as CVD, cancer, diabetes, ulcers, and genetic disorders such as cystic fibrosis have increased across the globe

Diabetes and obesity can result in increase in incidence and complexity of wounds such as infections, ulcerations, and surgical wounds, which require treatments and incur exorbitant medical expenses

Beyond established applications in treating multiple myeloma, lymphoma, leukemia, and autoimmune diseases, stem cells derived from adult sources are considered a novel treatment for diverse indications, including cardiovascular, musculoskeletal, endocrine, and neurologic disorders

Key Players Increased Investment in Research & Development of Regenerative Medicine

Increase in investment by private players and government organizations in the development of regenerative medicine is a major factor boosting the growth of the global market during the forecast period

The field of medicine is constantly developing as newer therapies and medicines are launched in the market. Numerous public-private institutes and companies are focused on conducting studies for developing innovative therapies.

In December 2020, Bayer AG launched a cell and gene therapy platform within its pharmaceutical division. Moreover, growing product pipeline is estimated to fuel market growth during the forecast period.

Costly Treatment Associated with Regenerative Medicine

Cell and gene therapies represent a significant scientific and medical achievement for patients suffering from terminal illnesses and serious disorders. These treatments assist in the transformation of how diseases are treated and possibly cured. Furthermore, such therapies will in future allow doctors and medical professionals to inject genes/cells into patients instead of using a series of medications and undergoing many surgeries.

However, despite the fact that these therapies are lifesavers and more effective than standard treatments, demand for these therapies is lower than anticipated. This is due to high cost of these therapies as well as the difficulties in securing reimbursements and coverage.

by Competition Landscape

This report profiles major players in the global regenerative medicine market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments

The global regenerative medicine market is highly fragmented due to presence of a number of international as well as regional players

Leading players operating in the global regenerative medicine market are Smith & Nephew plc, Anika Therapeutics, Inc., DePuy Synthes, Inc., Baxter International, Inc., Stryker Corporation, Medtronic, Inc., Arthrex, Inc., Zimmer Holdings, Inc., and CONMED Corporation, among others

by Key Developments

Key players in the global regenerative medicine market are engaged in regulatory approvals, technologically advanced products, launch of new products, and acquisition & collaborative agreements with other companies. These strategies are likely to fuel the growth of the global regenerative medicine market. A few expansion strategies adopted by players operating in the global regenerative medicine market are:

In February 2020, Stryker Corporation acquired Wright Medical to expand its product portfolio

In October 2020, Thermo Fisher Scientific, Inc. launched the Gibco CTS Rotea Counterflow Centrifugation System, a closed cell therapy processing system for the development and manufacturing of scalable and cost-effective cell therapy

In September 2018, NuVasive, Inc. announced the commercial launch of three novel biologics aids to the current Propel DBM product range, including conventional bone allograft, amniotic membrane DS, and additional form factors.

The report on the global regenerative medicine market discussed individual strategies, followed by company profiles of manufacturers of regenerative medicine devices. The competitive landscape section has been included in the report to provide readers with a dashboard view and a company market share analysis of key players operating in the global regenerative medicine market.

Key Questions Answered in Regenerative Medicine Market Report

  • What is the scope of growth of product companies in the global regenerative medicine market?
  • What will be the Y-o-Y growth of the global regenerative medicine market between 2021 and 2028?
  • What is the influence of changing trends in technologies on the global regenerative medicine market?
  • Will North America continue to be the most profitable market for regenerative medicine devices providers?
  • Which factors are anticipated to hamper the growth of the global regenerative medicine market during the forecast period?
  • Which are the leading companies in the global regenerative medicine market?.

Regenerative Medicine Market – Segmentation

Technology

  • Biomaterials
  • Stem Cells
  • Tissue Engineering

Application

  • Bone Graft Substitutes
  • Osteoarticular Diseases
  • Allogeneic Bones
  • Autogenic Bones
  • Others

Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

TABLE OF CONTENT

1. Preface

1.1. Market Definition and Scope

1.2. Market Segmentation

1.3. Key Research Objectives

1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Regenerative Medicines Market

4. Market Overview

4.1. Introduction

4.1.1. Technology Definition

4.1.2. Industry Evolution / Developments

4.2. Overview

4.3. Market Dynamics

4.3.1. Drivers

4.3.2. Restraints

4.3.3. Opportunities

4.4. Global Regenerative Medicines Market Analysis and Forecast, 2017–2028

5. Key Insights

5.1. Technological Advancements

5.2. Key Mergers & Acquisitions

5.3. Regulatory Scenario by Region/globally

5.4. COVID-19 Pandemics Impact on Industry

6. Global Regenerative Medicines Market Analysis and Forecast, by Technology

6.1. Introduction & Definition

6.2. Key Findings / Developments

6.3. Market Value Forecast, by Technology, 2017–2028

6.3.1. Stem Cell

6.3.2. Biomaterial

6.3.3. Tissue Engineering

6.4. Market Attractiveness Analysis, by Technology

7. Global Regenerative Medicines Market Analysis and Forecast, by Application

7.1. Introduction & Definition

7.2. Key Findings / Developments

7.3. Market Value Forecast, by Application, 2017–2028

7.3.1. Bone Graft Substitutes

7.3.2. Osteoarticular Diseases

7.3.3. Allogeneic Bones

7.3.4. Autogenic Bones

7.3.5. Others

7.4. Market Attractiveness Analysis, by Application

8. Global Regenerative Medicines Market Analysis and Forecast, by Region

8.1. Key Findings

8.2. Market Value Forecast, by Region

8.2.1. North America

8.2.2. Europe

8.2.3. Asia Pacific

8.2.4. Latin America

8.2.5. Middle East & Africa

8.3. Market Attractiveness Analysis, by Region

9. North America Regenerative Medicines Market Analysis and Forecast

9.1. Introduction

9.1.1. Key Findings

9.2. Market Value Forecast, by Technology, 2017–2028

9.2.1. Stem Cell

9.2.2. Biomaterial

9.2.3. Tissue Engineering

9.3. Market Value Forecast, by Application, 2017–2028

9.3.1. Bone Graft Substitutes

9.3.2. Osteoarticular Diseases

9.3.3. Allogeneic Bones

9.3.4. Autogenic Bones

9.3.5. Others

9.4. Market Value Forecast, by Country, 2017–2028

9.4.1. U.S.

9.4.2. Canada

9.5. Market Attractiveness Analysis

9.5.1. By Technology

9.5.2. By Application

9.5.3. By Country

10. Europe Regenerative Medicines Market Analysis and Forecast

10.1. Introduction

10.1.1. Key Findings

10.2. Market Value Forecast, by Technology, 2017–2028

10.2.1. Stem Cell

10.2.2. Biomaterial

10.2.3. Tissue Engineering

10.3. Market Value Forecast, by Application, 2017–2028

10.3.1. Bone Graft Substitutes

10.3.2. Osteoarticular Diseases

10.3.3. Allogeneic Bones

10.3.4. Autogenic Bones

10.3.5. Others

10.4. Market Value Forecast, by Country/Sub-region, 2017–2028

10.4.1. Germany

10.4.2. U.K.

10.4.3. France

10.4.4. Italy

10.4.5. Spain

10.4.6. Rest of Europe

10.5. Market Attractiveness Analysis

10.5.1. By Technology

10.5.2. By Application

10.5.3. By Country/Sub-region

11. Asia Pacific Regenerative Medicines Market Analysis and Forecast

11.1. Introduction

11.1.1. Key Findings

11.2. Market Value Forecast, by Technology, 2017–2028

11.2.1. Stem Cell

11.2.2. Biomaterial

11.2.3. Tissue Engineering

11.3. Market Value Forecast, by Application, 2017–2028

11.3.1. Bone Graft Substitutes

11.3.2. Osteoarticular Diseases

11.3.3. Allogeneic Bones

11.3.4. Autogenic Bones

11.3.5. Others

11.4. Market Value Forecast, by Country/Sub-region, 2017–2028

11.4.1. China

11.4.2. Japan

11.4.3. India

11.4.4. Australia & New Zealand

11.4.5. Rest of Asia Pacific

11.5. Market Attractiveness Analysis

11.5.1. By Technology

11.5.2. By Application

11.5.3. By Country/Sub-region

12. Latin America Regenerative Medicines Market Analysis and Forecast

12.1. Introduction

12.1.1. Key Findings

12.2. Market Value Forecast, by Technology, 2017–2028

12.2.1. Stem Cell

12.2.2. Biomaterial

12.2.3. Tissue Engineering

12.3. Market Value Forecast, by Application, 2017–2028

12.3.1. Bone Graft Substitutes

12.3.2. Osteoarticular Diseases

12.3.3. Allogeneic Bones

12.3.4. Autogenic Bones

12.3.5. Others

12.4. Market Value Forecast, by Country/Sub-region, 2017–2028

12.4.1. Brazil

12.4.2. Mexico

12.4.3. Rest of Latin America

12.5. Market Attractiveness Analysis

12.5.1. By Technology

12.5.2. By Application

12.5.3. By Country/Sub-region

13. Middle East & Africa Regenerative Medicines Market Analysis and Forecast

13.1. Introduction

13.1.1. Key Findings

13.2. Market Value Forecast, by Technology, 2017–2028

13.2.1. Stem Cell

13.2.2. Biomaterial

13.2.3. Tissue Engineering

13.3. Market Value Forecast, by Application, 2017–2028

13.3.1. Bone Graft Substitutes

13.3.2. Osteoarticular Diseases

13.3.3. Allogeneic Bones

13.3.4. Autogenic Bones

13.3.5. Others

13.4. Market Value Forecast, by Country/Sub-region, 2017–2028

13.4.1. GCC Countries

13.4.2. South Africa

13.4.3. Rest of Middle East & Africa

13.5. Market Attractiveness Analysis

13.5.1. By Technology

13.5.2. By Application

13.5.3. By Country/Sub-region

14. Competition Landscape

14.1. Market Player – Competition Matrix (by tier and size of companies)

14.2. Market Share Analysis, by Company, 2020

14.3. Company Profiles

14.3.1. Smith & Nephew plc

14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

14.3.1.2. Financial Analysis

14.3.1.3. Growth Strategies

14.3.1.4. SWOT Analysis

14.3.2. Anika Therapeutics, Inc.

14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

14.3.2.2. Financial Analysis

14.3.2.3. Growth Strategies

14.3.2.4. SWOT Analysis

14.3.3. DePuy Synthes, Inc.

14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

14.3.3.2. Financial Analysis

14.3.3.3. Growth Strategies

14.3.3.4. SWOT Analysis

14.3.4. Baxter International, Inc.

14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

14.3.4.2. Financial Analysis

14.3.4.3. Growth Strategies

14.3.4.4. SWOT Analysis

14.3.5. Stryker Corporation

14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

14.3.5.2. Financial Analysis

14.3.5.3. Growth Strategies

14.3.5.4. SWOT Analysis

14.3.6. Medtronic, Inc.

14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

14.3.6.2. Financial Analysis

14.3.6.3. Growth Strategies

14.3.6.4. SWOT Analysis

14.3.7. Arthrex Inc.

14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

14.3.7.2. Financial Analysis

14.3.7.3. Growth Strategies

14.3.7.4. SWOT Analysis

14.3.8. Zimmer Holdings, Inc.

14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

14.3.8.2. Financial Analysis

14.3.8.3. Growth Strategies

14.3.8.4. SWOT Analysis

14.3.9. CONMED Corporation

14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

14.3.9.2. Financial Analysis

14.3.9.3. Growth Strategies

14.3.9.4. SWOT Analysis

 

Purchase Complete Report Now@ https://qyresearchmedical.com/report/checkout/111476/2900

You can place an order or ask any questions, please feel free to contact at mailto:sales@qyresearchmedical.com | +1 9197 992 333

About Us

QYResearch Medical, focuses on custom research, management consulting, IPO consulting, industry chain research, and data base & seminar services. The company owns large basic databases (such as National Bureau of Statistics Database, Customs Import and Export Database, Industry Association Database, etc.), expert resources (including industry experts who own more than 10 years experiences on marketing or R&D in industries of healthcare services, medical technology & devices, etc.), professional survey team (the team members obtained more than 3 years market survey experience and more than 2 years deep expert interview experience), and excellent data analysis team (SPSS statistics and PPT graphics process team).

QYResearch Medical has more than 4000 global well-known customers, covering more than 30 industries including pharmaceuticals, medical technology & devices, healthcare services etc. Company services cover one-stop solution as Data-Analysis-Suggestion-Consulting Implementation. Research regions cover China, US, EU, Asia, Middle East and Africa, South America, Australia, and other regions in the world.

For Latest Update Follow Us:

https://www.linkedin.com/company/qyresearch-medical/

https://www.facebook.com/QYResearch-Medical-108186514228917/

https://twitter.com/qyresearchmedi